blahblahblah|blahblahblah
Trebuchet MS|NSimSum
>Name|>姓名
>Patient ID|>病人编号
>Birthdate|>出生日期
>Sample ID|>样品编号
>Secondary ID|>副编号
>Sample Date|>取样日期
>Report Date|>报告日期
>Patient Details|>病人详情
>Test Details|>测试细节
>Physician Details|>医生详情
>For research use only|>仅用于科研
>HIV Resistance Genotype report|>HIV 耐药基因型报告
>Lamivudine|>拉米夫定
>Abacavir|>硫酸阿波卡韦
>Zidovudine|>齐多夫定
>Stavudine|>司他夫定
>Didanosine|>去羟肌苷
>Emtricitabine|>恩曲他滨
>Tenofovir|>替诺福韦
>Delavirdine|>Delavirdine
>Efavirenz|>依法韦仑
>Etravirine|>依曲韦林
>Nevirapine|>奈韦拉平
>Enfuvirtide|>恩夫韦肽
>Rilpivirine|>利匹韦林
>Atazanavir/r|>阿扎那韦/利托那韦
>Darunavir/r|>地瑞那韦/利托那韦
>Fosamprenavir/r|>福沙那伟/利托那韦
>Indinavir/r|>茚地那韦/利托那韦
>Lopinavir/r|>洛匹那韦/利托那韦
>Nelfinavir|>奈非那韦
>Saquinavir/r|>沙奎那韦/利托那韦
>Tipranavir/r|>替拉那韦/利托那韦
>Elvitegravir|>埃替拉韦
>Raltegravir|>拉替拉韦
>Dolutegravir|>德罗格韦
>Maraviroc|>马拉韦罗
>None|>无
>V3 Loop Tropism|>V3 环的基因型取向
>Susceptible|>有效
>Low-level resistance|>低度耐药性
>Intermediate resistance|>中度耐药性
>High-level resistance|>高度耐药性
>Resistant|>耐药性
>Possible resistance|>可能有耐药性
>Inferred Amino Acid Sequence|>推断时采用的氨基酸序列
>Not Susceptible|>无效
>Non-R5|>非R5
>Tropism:|>基因型取向:
>Specimens with a geno2pheno false positive rate above|>标本geno2pheno的假阳性率如超过
 are considered R5, while those below| ，被认为是：R5，如低于
 are considered non-R5.| ，则被认为是： 非R5.
>Sequence quality was not sufficient to obtain a result|>基因排序数据没达到质量标准，无法获得结果
Email:|电邮:
>Date Printed|>打印日期
>Version|>版本
, modified on|, 于
<!--moddate-->|修改
<!--day-->|日
<!--month-->-|月
<!--year-->-|年
The genotyping assay was developed and its performance characteristics determined by the testing laboratory. The sequence results were generated by the testing laboratory, and sequence interpretation performed via an automated service at the BC Centre for Excellence in HIV/AIDS.  The BC Centre cannot be held responsible for the quality, integrity and correctness of the sequence results, or for the correctness of the patient demographic data added to this report. For US clients, this report has not been cleared or approved by the U.S. Food and Drug Administration.   Interpretation is done by Stanford HIV Web Service Sierra for protease/RT sequences or the an adaptation of the geno2pheno co-receptor algorithm for V3 sequences.  Please see these websites for further information: http://hivdb.stanford.edu/pages/webservices/ or http://coreceptor.bioinf.mpi-inf.mpg.de/.|此报告是根据地方测试实验室提供的基因排序数据，经由本中心全自动解读流程服务器解读而成。基因分型测试方法及其性能特点是由地方测试实验室研发，完成和决定的。 BC 艾滋卓越中心无法对基因排序数据的质量 完整性和正确性提供保证和负责。更无法对后期填入的病人个人信息的正确性提供保证和负责。对蛋白酶/ 逆转录酶基因排序的解读是通过斯坦福大学艾滋病毒网路服务器“塞拉利昂” 完成的。对共受体基因型取向的解读是根据V3基因排序，参照geno2pheno 共受体算法解读而成。请到这些网站获取详情 http://hivdb.stanford.edu/pages/webservices/ or http://coreceptor.bioinf.mpi-inf.mpg.de/.
>NRTI/NtRTI Drugs|>核苷/核苷酸类药
>PI Drugs|>蛋白酶抑制剂
>NNRTI Drugs|>非核苷类药
>Integrase Drugs|>整合酶抑制剂
>GP41 Drugs|>融合抑制剂
>Relevant PI Mutations|>与蛋白酶抑制剂相关的基因突变
>Relevant NRTI/NtRTI/NNRTI Mutations|>与NRTI/NtRTI/NNRTI相关的基因突变
>Relevant Integrase Mutations|>与整合酶抑制剂相关的基因突变
>Relevant GP41 Mutations|>与融合抑制剂相关的基因突变
>Co-Receptor Antagonists|>共受体拮抗剂
>Generated by WebRecall at the BC Centre for Excellence|>由BC艾滋卓越中心的WebRecall处理，呈报
>Resistance Call|>耐药性结果
>Cut-off|>界限值
>FC|><text style="font-size:7px;" dx="-4">倍数变化</text>
The genotyping assay was developed and its performance characteristics determined by the testing laboratory. The sequence results were generated by the testing laboratory, and sequence interpretation performed via an automated service at the BC Centre for Excellence in HIV/AIDS.  The BC Centre cannot be held responsible for the quality, integrity and correctness of the sequence results, or for the correctness of the patient demographic data added to this report. For US clients, this report has not been cleared or approved by the U.S. Food and Drug Administration.  Interpretation is done by Stanford HIV Web Service Sierra, or using a database of linked genotype and phenotype data to provide estimates for the degree of phenotypic change for protease/RT sequences.  Alternatively, it uses an adaptation of the geno2pheno co-receptor algorithm for V3 sequences.  Please see these websites for further information: http://hivdb.stanford.edu/pages/webservices/ or http://coreceptor.bioinf.mpi-inf.mpg.de/.|此报告是根据地方测试实验室提供的基因排序数据，经由BC艾滋卓越中心全自动解读流程服务器解读而成。 基因分型测试方法，及其性能，特点是由地方测试实验室研发，完成和决定的。本中心无法对基因排序数据的质量, 完整性和正确性提供保证和负责。更无法对后期填入的病人的个人信息的正确性提供保证和负责。 美国用户： 本报告未经美国食品和药物管理局审核批准。 基因排序数据的解读，使用了斯坦福大学艾滋病毒网路服务器“塞拉利昂”，和一个能将基因型和表型联合对比的数据库。它依据蛋白酶/ 逆转录酶的基因排序，来估算其表型改变的程度。另外，对共受体基因型取向的解读是根据V3基因排序， 采用 geno2pheno共受体算法完成。请查阅以下网站获取更多信息：  http://hivdb.stanford.edu/pages/webservices/ 或 http://coreceptor.bioinf.mpi-inf.mpg.de/
>Reduced Response|>对药物的敏感性降低
>Resistance|>耐药性